Volume 23, Number 3—March 2017
Dispatch
pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia
Table 2
pncA gene sequencing results of 93 MDR TB and 10 XDR TB isolates from Georgia*
| Mutation |
pncA mutation type† |
Frequency (no. isolates) |
| Mutations specific to MDR TB isolates | ||
| 1 | CAG(Q) 141 CCG(P)‡ | 20 |
| 2 | CAT(H) 71 CGT(R)‡ | 8 |
| 3 | CAT(H) 71 CCT(P)‡ | 6 |
| 4 | Ins C after 420, 421ΔA, CAG(Q) 141 CCG(P)‡ | 3 |
| 5 | TGG(W) 119 TTG(L)‡ | 3 |
| 6 | ATC(I) 6 CTC(L)§ | 2 |
| 7 | GAC(D) 49 GGC(G)‡ | 2 |
| 8 | CCA(P) 69 CGA(R)‡ | 2 |
| 9 | GTG(V) 155 GCG(A)§ | 2 |
| 10 | TTG(L) 4 TGG(W)‡ | 1 |
| 11 | ATC(I) 5 ACC(T)§ | 1 |
| 12 | CTG(L) 27 CCG(P)‡ | 1 |
| 13 | GAC(D) 49 GAG(E)‡ | 1 |
| 14 | CAC(H) 51 TAC(Y)‡ | 1 |
| 15 | CCG(P) 54 CAG(Q)‡ | 1 |
| 16 | GAC(D) 63 GCC(A)‡ | 1 |
| 17 | TCG(S) 66 CCG(P)‡ | 1 |
| 18 | CAT(H) 71 CCT(P); Ins G after 547 (after G in GTT) | 1 |
| 19 | GGT(G) 97 AGT(S)‡ | 1 |
| 20 | TAC(Y) 103 TAA(Ter)‡ | 1 |
| 21 | TAC(Y) 103 TAG(Ter)‡ | 1 |
| 22 | GCC(A) 134 CCC(P) | 1 |
| 23 | ACG(T) 142 ATG(M)‡ | 1 |
| 24 | GGT(G) 162 TGT(C) | 1 |
| 25 | TGA(Ter) 187 CGA(R)§ | 1 |
| 26 | Del A at 298 | 1 |
| 27 | Ins A after 389 (after T in GTG) | 1 |
| 28 |
Ins G after 449 (after sec G in GGC) |
1 |
| Wild type |
26 |
|
| Mutations specific to XDR TB isolates | ||
| 1 | GTC(V) 7 GCC(A)‡ | 2 |
| 2 | ACC(T) 47 AGC(S)‡ | 2 |
| 3 | Ins TCT after 40 (after T In TGC) | 1 |
| 4 | GGC(G) 78 GAC(D)‡ | 1 |
| 5 | GGT(G) 97 CGT(R)‡ | 1 |
| 6 | TAC(Y) 103 GAC(D)‡ | 1 |
| 7 | GGC(G) 105 CGC(R) | 1 |
| Wild type | 1 | |
*del, deletion; ins, insertion; MDR, multidrug resistant; SNP, single-nucleotide polymorphism; TB, tuberculosis; XDR, extensively drug resistant. Row colors: pink, frameshift mutations: insertions or deletions; green, synonymous mutations or SNPs reported as being associated with phenotypic susceptibility to pyrazinamide; gray, SNPs reported as being associated with phenotypic resistance to pyrazinamide; blue, SNPs not previously reported in the literature.
†Insertion and deletions are presented with the nucleotide position where the polymorphism occurred; single nucleotide polymorphisms are presented with the codon position and the original and mutated three nucleotides and amino acid
‡Reported in the literature as being associated with resistance to pyrazinamide.
§Reported in the literature as being associated with susceptibility to pyrazinamide.